drugset
drugset / Trial / NCT04565990

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

NCT04565990 ↗

Phase 3 Completed 43 enrolled Actelion
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.

Timeline

Start
2021-05-03
Primary completion
2023-11-10
Completion
2023-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Selexipag Small molecule 200 ug Oral
Subject Selexipag Small molecule 400 ug Oral
Subject Selexipag Small molecule 600 ug Oral
Subject Selexipag Small molecule 800 ug Oral
Subject Selexipag Small molecule 1000 ug Oral
Subject Selexipag Small molecule 1200 ug Oral
Subject Selexipag Small molecule 1400 ug Oral
Subject Selexipag Small molecule 1600 ug Oral

Indications

pulmonary hypertension